TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07719920: A Phase I Study Evaluating the Safety, Pharmacokinetics, and Efficacy of HW221043 Tablets in Participants With Advanced Solid Tumors

Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 99 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07719920 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07719920 Rescue Dossier →